Complera
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2022 | $36.25 | 1 | 1 |
| 2019 | $62.08 | 2 | 2 |
| 2018 | $19,103 | 1 | 0 |
| 2017 | $86,042 | 2 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $105,069 | 2 | 99.8% |
| Food and Beverage | $173.83 | 4 | 0.2% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Prospective, Single-Arm, Open-Label Study to Evaluate the Effect of Fixed-Dose Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate on T-Cell Activation, Absolute CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir in Treatment-Naive HIV-1 Controllers | Gilead Sciences Inc | $85,966 | 0 |
| A Prospective, Single-Arm, Open-Label Study to Evaluate the Effect of Fixed-Dose Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate on T-Cell Activation, Absolute CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir in Treatment-Naive HIV-1 Controllers | Gilead Sciences, Inc. | $19,103 | 0 |
Manufacturing Companies
- Gilead Sciences Inc $86,042
- Gilead Sciences, Inc. $19,201
Product Information
- Type Drug
- Total Payments $105,243
- Total Doctors 3
- Transactions 6
About Complera
Complera is a drug associated with $105,243 in payments to 3 healthcare providers, recorded across 6 transactions in the CMS Open Payments database. The primary manufacturer is Gilead Sciences Inc.
Payment data is available from 2017 to 2022. In 2022, $36.25 was paid across 1 transactions to 1 doctors.
The most common payment nature for Complera is "Unspecified" ($105,069, 99.8% of total).
Complera is associated with 2 research studies, including "A Prospective, Single-Arm, Open-Label Study to Evaluate the Effect of Fixed-Dose Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate on T-Cell Activation, Absolute CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir in Treatment-Naive HIV-1 Controllers" ($85,966).